Page 4 - Obesity

Biocon launches drug Liraglutide for diabetes, Biolide for obesity in UK

Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK. The GLP-1 peptide, Liraglutide, will be marketed in the UK under the brand names Liraglutide Biocon for diabetes and Biolide for chronic weight management, the company said in a statement. The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, earlier this year, making Biocon Ltd the first generics company to obtain approval for gLiraglutide in a major regulated market, it added. "The timely launch will offer healthcare providers and patients affordable access to this drug and help fulfil an unmet need," Biocon CEO and MD Siddharth Mittal said. The company will continue to focus its efforts towards expanding the reach of gLiraglutide into other European markets, the US and select geographies, he added. Glucagon-like peptide-1 (GLP-1) are medications that help lower blood sugar levels and promote weight loss. Liraglutid

PM Modi picks Omar Abdullah, 9 others for nationwide anti-obesity drive

PM Modi nominates Omar Abdullah, 9 others for anti-obesity campaign, urging for a nationwide movement to reduce oil consumption and promote a healthier India

Global pharma eyes India's obesity mkt, but weight-loss drugs face hurdles

These drugs belong to a class known as glucagon-like peptide receptor agonists (GLP-1RAs), which mimic a natural hormone that helps regulate blood sugar and appetite

PM Modi's push for obesity fight draws praise from medical fraternity

Co-Chair of the CII Public Health Council and Director of ITC Healthcare, Dr Sunil Chandy, said that the Prime Minister's obesity is the new epidemic that is affecting the Indian population

Proposed obesity benchmark adds organ health, daily functionality metrics

The recommendation signals a long-awaited shift from a single imperfect metric toward a more personalised diagnosis

Dr Morepen forays into wellness segment with weight management initiative

Dr Morepen on Tuesday forayed into the growing wellness segment with the launch of a weight management initiative. The company, a fully-owned subsidiary of Morepen Laboratories, is looking to establish itself in the segment which is currently valued at around Rs 12,000 crore and growing at an annual rate of 16 per cent. The company has launched its wellness product -- LightLife -- designed to tackle India's growing obesity crisis. India's obesity rate is increasing and this segment is expected to touch USD 52.3 billion by 2032, "reflecting the urgency to address weight management with solutions that are both safe and effective," Dr Morepen CEO Varun Suri said. With LightLife the company is looking to address the obesity issue without crash diets or harmful fads, he stated. According to the World Obesity Atlas 2024, over 25 per cent of Indian adults are projected to face obesity by 2035. Suri said the company's initiative is about promoting a healthy balanced lifestyle through ...

Eli Lilly to launch its obesity drug at competitive price in India in 2025

Lilly's rival Danish firm Novo Nordisk is also working to bring its obesity drug Wegovy (Semaglutide) to India soon, and according to reports the company may launch Wegovy in 2026

Eli Lilly to boost weight-loss drug supply with $3 billion expansion

The company's s blockbuster weight-loss and diabetes drugs have made it the most valuable pharmaceutical company in the world

Lilly's tirzepatide challenges semaglutide in obesity drug market

The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem

Need to recognise obesity as chronic disease for better management: Experts

There is a disconnect between awareness, understanding and management of obesity and recognising it as a chronic disease will be the first step towards obesity management, experts have said. A recent report by global healthcare company Novo Nordisk, that involved more than 2,000 people living with obesity (PwO) and 300 healthcare professionals in India, underlined the need for an integrated, long-term approach to the treatment of obesity. PwO face immense difficulties in maintaining weight loss and more than half of those surveyed said they reverted to old eating habits despite their efforts to change. More than 44 per cent regain lost weight within six months, the report said, emphasising the need for more sustainable, long-term solutions that go beyond just lifestyle adjustments. "The first step towards obesity management is to understand that it is a chronic disease. We need to support People with Obesity (PwO) with tools that not only help them lose weight but also maintain tha

Novo Nordisk posts Q3 sales of obesity drug Wegovy above expected forecast

The Denmark-based company said it now expects sales growth this year of between 23% and 27% in local currencies, compared to the previously guided range for 22% to 28% growth

Obesity medicines would cost US medicare $35 billion through 2034

Expanding coverage of weight-loss drugs like blockbusters from Eli Lilly & Co. and Novo Nordisk A/S would make 12.5 million more people in the US program eligible

EU regulator backs use of Novo's Wegovy for obesity related heart condition

It also improved physical limitations and exercise function in patients with the condition, Novo said

Obesity-linked cancer rates surge in China; young adults most affected

From 2007 to 2021, obesity-related cancer rates in China rose by 3.6% annually, with a striking 15.3% increase for those aged 25 to 29, while rates for non-obesity-linked cancers stayed stable

Waist-to-height ratio more effective than BMI for obesity diagnosis: Study

Obesity can no longer be just defined by body mass index (BMI) and rather should be about how body fat is distributed throughout one's body, researchers said while launching a new framework for diagnosing and managing obesity. Published in the journal Nature Medicine, the framework looks specifically at fat accumulated in the abdomen, measured as 'waist-to-height ratio' -- an increased value of which is related to a higher risk of developing cardiometabolic complications, according to the researchers. An "important novelty" of the framework is including a waist-to-height ratio higher than 0.5, along with a BMI of 25-30, for diagnosing obesity, the authors, representing the European Association for the Study of Obesity (EASO), said. "The choice of introducing waist-to-height ratio, instead of waist circumference, in the diagnostic process is due to its superiority as a cardiometabolic disease risk marker," they wrote. Accumulation of abdominal fat is a more reliable predictor of hea

Govt panel urges drug regulator to approve Lilly's obesity drug Mounjaro

Lilly should also submit the required manufacturing and controls data, the expert panel added

Obesity and more: What can prevent you from applying for health insurance?

Are you aware that your obesity might prevent you from being granted a health insurance policy? Or that your premiums could be higher if you drink alcohol or smoke?

Big plans ahead: Cipla looks for shot in the arm in niche areas

Open to licensing, collaboration in anti-diabetes space

Eli Lilly expects to launch obesity drug in India next year, says CEO

Mounjaro, chemically known as tirzepatide, is currently sold in the UK and Europe under the same brand name for both conditions

Ozempic's massive bills: Weight loss drugs will be billed to US taxpayers

State and local governments across the US are grappling with a growing problem: Expensive drugs to treat diabetes and obesity are threatening to drain their health-care budgets